MicroRNA expression in human endometrial adenocarcinoma

Cancer Cell International

Karin Klinga-Levan²  Björn Olsson¹  Sanja Jurcevic² 

[1] Systems Biology Research Centre - Bioinformatics, Bio Science, University of Skövde, Skövde, Sweden;Systems Biology Research Centre - Tumor Biology, Bio Science, University of Skövde, SE541 28, Skövde, Sweden

关键词: Quantitative polymerase chain reaction;    MicroRNA;    Endometrial adenocarcinoma;   

Others  :  1121633
DOI  :  10.1186/s12935-014-0088-6

 received in 2014-04-08, accepted in 2014-08-26,  发布年份 2014

【 摘 要 】

Background

MicroRNAs are small non-coding RNAs that play crucial roles in the pathogenesis of different cancer types. The aim of this study was to identify miRNAs that are differentially expressed in endometrial adenocarcinoma compared to healthy endometrium. These miRNAs can potentially be used to develop a panel for classification and prognosis in order to better predict the progression of the disease and facilitate the choice of treatment strategy.

Methods

Formalin fixed paraffin embedded endometrial tissue samples were collected from the Örebro university hospital. QPCR was used to quantify the expression levels of 742 miRNAs in 30 malignant and 20 normal endometrium samples. After normalization of the qPCR data, miRNAs differing significantly in expression between normal and cancer samples were identified, and hierarchical clustering analysis was used to identify groups of miRNAs with coordinated expression profiles.

Results

In comparisons between endometrial adenocarcinoma and normal endometrium samples 138 miRNAs were found to be significantly differentially expressed (p < 0.001) among which 112 miRNAs have not been previous reported for endometrial adenocarcinoma.

Conclusion

Our study shows that several miRNAs are differentially expressed in endometrial adenocarcinoma. These identified miRNA hold great potential as target for classification and prognosis of this disease. Further analysis of the differentially expressed miRNA and their target genes will help to derive new biomarkers that can be used for classification and prognosis of endometrial adenocarcinoma.

【 授权许可】

   
2014 Jurcevic et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
• [2]Cavanagh D, Fiorica J, Hoffman M, Durfee J, Nicosia S: Adenocarcinoma of the endometrium: an institutional review. Cancer Control 1999, 6:354-360.
• [3]Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W: Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000, 7:227-242.
• [4]Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I: Endometrial cancer. Lancet 2005, 366:491-505.
• [5]Lee Y, Jeon K, Lee J, Kim S, Kim V: MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002, 21:4663-4670.
• [6]Sassen S, Miska EA, Caldas C: MicroRNA: implications for cancer. Virchows Arch 2008, 452:1-10.
• [7]Michael MZ, O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1:882-891.
• [8]Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci 2002, 99:15524.
• [9]Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65:9628-9632.
• [10]Fassina A, Marino F, Siri M, Zambello R, Ventura L, Fassan M, Simonato F, Cappellesso R: The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Investig 2012, 92:1574-1582.
• [11]Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P: Unlocking the archive–gene expression in paraffin-embedded tissue. J Pathol 2001, 195:66-71.
• [12]Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42.
• [13]Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13:1668-1674.
• [14]Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CM: Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 2012, 107:684-694.
• [15]Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H: An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 2008, 10:513-519.
• [16]Cohn D, Fabbri M, Valeri N, Alder H, Ivanov I, Liu C, Croce C, Resnick K: Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol 2010, 202:656.e-.e8.
• [17]Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 2009, 18:50-55.
• [18]Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D-T, Dressman H, Lancaster JM: MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 2008, 110:206-215.
• [19]Chung TKH, Cheung T-H, Huen N-Y, Wong KWY, Lo KWK, Yim S-F, Siu NSS, Wong Y-M, Tsang P-T, Pang M-W, Yu M-Y, To K-F, Mok SC, Wang VW, Li C, Cheung AYK, Doran G, Birrer MJ, Smith DI, Wong Y-F: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 2009, 124:1358-1365.
• [20]Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R: Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 2013, 132:1633-1645.
• [21]Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol 2010, 118:251-257.
• [22]Catasus L, Pons C, Munoz J, Espinosa I, Prat J: Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas. Histopathology 2013, 62:632-641.
• [23]Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K: TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29:1787-1797.
• [24]Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM: Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007, 27:7802-7815.
• [25]Bui TD, Zhang L, Rees MC, Bicknell R, Harris AL: Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer 1997, 75:1131-1136.
• [26]Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17:590-603.
• [27]Vadlakonda L, Pasupuleti M, Pallu R: Role of PI3K-AKT-mTOR and Wnt signaling pathways in transition of G1-S phase of cell cycle in cancer cells. Front Oncol 2013, 3:85.
• [28]Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
• [29]Lee JW, Park YA, Choi JJ, Lee YY, Kim CJ, Choi C, Kim TJ, Lee NW, Kim BG, Bae DS: The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol 2011, 120:56-62.
• [30]Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D: Biomarkers in endometrial cancer: possible clinical applications (Review). Oncol Lett 2012, 3:1175-1180.
• [31]Tsang WP, Kwok TT: The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009, 30:953-959.
• [32]Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC, Lempicki RA: DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics 2007, 8:426. BioMed Central Full Text
• [33]Schaeffer HJ, Weber MJ: Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999, 19:2435-2444.
• [34]Kim EK, Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802, 2010:396-405.
• [35]Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
• [36]Mitsuhashi Y, Horiuchi A, Miyamoto T, Kashima H, Suzuki A, Shiozawa T: Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology 2012, 60:826-837.
• [37]Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Oyan AM, Otte AP, Kalland KH, Akslen LA, Salvesen HB: Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer 2008, 98:1662-1669.
• [38]Caraux G, Pinloche S: PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 2005, 21:1280-1281.